Surendra Sidhu, MD
Family Medicine · Shelby, NCNPI 1740251651
Payments from drug & device makers
Across 627 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$1K
- Boehringer Ingelheim$691
- AbbVie$676
- Lilly USA, LLC$628
- Kowa Pharmaceuticals America, Inc.$566
- plus $4K from 28 others
What the payments were for
- Food & beverage$9,56098%
- Education$1912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 108 | $1,459 |
| AstraZeneca | 87 | $1,457 |
| Boehringer Ingelheim | 52 | $691 |
| AbbVie(2 entities) | 41 | $676 |
| Lilly USA, LLC | 39 | $628 |
| Kowa Pharmaceuticals America, Inc. | 49 | $566 |
| Johnson & Johnson | 33 | $544 |
| Pfizer | 37 | $502 |
| Amgen(2 entities) | 29 | $453 |
| Astellas Pharma US Inc | 16 | $422 |
| Sanofi-aventis U.S. LLC | 23 | $369 |
| Dexcom, Inc. | 12 | $247 |
| Novartis | 16 | $247 |
| Merck | 16 | $245 |
| GSK | 14 | $228 |
| Abbott | 9 | $166 |
| Preventric Diagnostics, Inc. | 2 | $125 |
| Hikma Pharmaceuticals USA | 8 | $118 |
| Genentech USA, Inc. | 6 | $96 |
| Bayer | 5 | $80 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $52 |
| Almatica Pharma LLC | 3 | $48 |
| Exact Sciences | 3 | $45 |
| Medicure Pharma Inc. | 1 | $33 |
| Eisai Inc. | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $29 |
| Ardelyx, Inc. | 1 | $26 |
| Acadia Pharmaceuticals Inc | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Viatris Specialty LLC | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,750 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 171 | $310,112 |
| EliquisApixaban | 77 | $93,611 |
| JanuviaSitagliptin Phosphate | 63 | $88,704 |
| RybelsusSemaglutide | 63 | $80,535 |
| MounjaroTirzepatide | 43 | $59,550 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $35,577 |
| JardianceEmpagliflozin | 26 | $33,350 |
| XareltoRivaroxaban | 22 | $23,956 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $23,347 |
| FarxigaDapagliflozin Propanediol | 28 | $22,272 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $18,549 |
| WegovySemaglutide | 13 | $17,443 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $16,475 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $16,354 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 11 | $15,436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $1,459 | $408,091247 claims |
| PfizerEliquis | $502 | $93,61177 claims |
| MerckJanuvia | $245 | $88,70463 claims |
| Lilly USA, LLCMounjaro | $628 | $59,55043 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,457 | $38,62643 claims |
| Boehringer IngelheimJardiance | $691 | $33,35026 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $228 | $28,84243 claims |
| Johnson & JohnsonXarelto | $544 | $23,95622 claims |
| AbbVieSynthroid | $676 | $5,00661 claims |
| Esperion Therapeutics, Inc.Nexletol | $15 | $4,70412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Shelby
- Christian MartinShelby$5.4M
- Stephen JonesShelby$4.5M
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.